Abstract
Non alcoholic fatty liver disease (NAFLD) is defined as fat accumulation exceeding 5% to 10% by the weight of the liver, in the absence of other causes of steatosis. NAFLD is strongly associated with metabolic diseases, such as metabolic syndrome. At present, insulin resistance, elevated concentrations of free fatty acids and oxidants, and an imbalance between different cytokines have been identified as the common pathophysiological elements underlying both NAFLD and metabolic syndrome. Emerging evidence also considers NAFLD as the hepatic manifestation of metabolic syndrome and supports a possible direct role of fat liver in cardiovascular risk assessment. Further investigations are needed to better understand the role of NAFLD, as an independent active factor in metabolic syndrome and associated cardiovascular disease.
Keywords: Atherosclerosis, metabolic syndrome, non-alcoholic fatty liver disease, cardiovascular risk
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Does Non-Alcoholic Fatty Liver Disease (NAFLD) Increase Cardiovascular Risk?
Volume: 8 Issue: 4
Author(s): Fabrizio Montecucco and Francois Mach
Affiliation:
Keywords: Atherosclerosis, metabolic syndrome, non-alcoholic fatty liver disease, cardiovascular risk
Abstract: Non alcoholic fatty liver disease (NAFLD) is defined as fat accumulation exceeding 5% to 10% by the weight of the liver, in the absence of other causes of steatosis. NAFLD is strongly associated with metabolic diseases, such as metabolic syndrome. At present, insulin resistance, elevated concentrations of free fatty acids and oxidants, and an imbalance between different cytokines have been identified as the common pathophysiological elements underlying both NAFLD and metabolic syndrome. Emerging evidence also considers NAFLD as the hepatic manifestation of metabolic syndrome and supports a possible direct role of fat liver in cardiovascular risk assessment. Further investigations are needed to better understand the role of NAFLD, as an independent active factor in metabolic syndrome and associated cardiovascular disease.
Export Options
About this article
Cite this article as:
Montecucco Fabrizio and Mach Francois, Does Non-Alcoholic Fatty Liver Disease (NAFLD) Increase Cardiovascular Risk?, Endocrine, Metabolic & Immune Disorders - Drug Targets 2008; 8 (4) . https://dx.doi.org/10.2174/187153008786848268
DOI https://dx.doi.org/10.2174/187153008786848268 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Characterizing the Binding of Angiotensin Converting Enzyme I Inhibitory Peptide to Human Hemoglobin: Influence of Electromagnetic Fields
Protein & Peptide Letters Association Between Chlamydia pneumoniae Antibodies and Lung Cancer: A Meta-Analysis
Current Respiratory Medicine Reviews Sepsis: Links between Pathogen Sensing and Organ Damage
Current Pharmaceutical Design Clozapine Safety, 35 Years Later
Current Drug Safety Chemical and Physical Properties and Potential Mechanisms: Melatonin as a Broad Spectrum Antioxidant and Free Radical Scavenger
Current Topics in Medicinal Chemistry Mechanical Design and Control Method for SEA and VSA-based Exoskeleton Devices for Elbow Joint Rehabilitation
Neuroscience and Biomedical Engineering (Discontinued) The Medicinal Chemistry of Genus <i>Aralia</i>
Current Topics in Medicinal Chemistry Autoimmune Hepatitis: Pathophysiology, Diagnosis and Pharmacological Therapy
Current Immunology Reviews (Discontinued) Identification and Treatment of Patients with Homozygous Familial Hypercholesterolaemia: Information and Recommendations from a Middle East Advisory Panel
Current Vascular Pharmacology Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Current Pharmaceutical Design Efficacy of Chemopreventive Agents in Mouse Mammary Gland Organ Culture (MMOC) Model: A Comprehensive Review
Current Medicinal Chemistry A Review of Patents Relating to Therapeutic Angiogenesis Using Endothelial Progenitors and Other Vasculogenesis-Related Cell Types
Recent Patents on Regenerative Medicine An Update on Natural Occurrence and Biological Activity of Chromones
Current Medicinal Chemistry Chronic Inflammatory Diseases and the Acute Respiratory Distress Syndrome (ARDS)
Current Pharmaceutical Design Inhibitors of Catechol-O-methyltransferase in the Treatment of Neurological Disorders
Central Nervous System Agents in Medicinal Chemistry Olive Oil-related Anti-inflammatory Effects on Atherosclerosis: Potential Clinical Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets Coronary Artery Disease and Endothelial Dysfunction: Novel Diagnostic and Therapeutic Approaches
Current Medicinal Chemistry Adrenal Hyperandrogenism and Polycystic Ovary Syndrome
Current Pharmaceutical Design Cardiovascular Magnetic Resonance for Evaluation of Heart Involvement in ANCA-Associated Vasculitis. A Luxury or a Valuable Diagnostic Tool?
Inflammation & Allergy - Drug Targets (Discontinued) Recent Patents on PCSK9: A New Target for Treating Hypercholesterolemia
Recent Patents on DNA & Gene Sequences